{"filing":{"accession_number":"0001213900-26-083563","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0299917-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026083563/ea0299917-8k_jasper.htm"},"events":[{"id":22809,"run_id":20643,"accession_number":"0001213900-26-083563","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"This Item 8.01 disclosure concerns the contingent value rights (CVRs) structure established in connection with Jasper Therapeutics' acquisition of Kira Pharmaceuticals, which closed on July 16, 2026. The filing confirms the record date for CVR eligibility and describes the $30 million milestone payment contingent on FDA Priority Review Voucher issuance for briquilimab by December 31, 2028. While technically an \"Other Events\" item, the substance is a material acquisition completion with contingent consideration terms, making this a follow-up disclosure to the M\u0026A activity previously reported on the Prior Form 8-K filed July 16, 2026.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22872,"accession_number":"0001213900-26-083563","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 8.01 disclosure concerns the contingent value rights (CVRs) structure established in connection with Jasper Therapeutics' acquisition of Kira Pharmaceuticals, which closed on July 16, 2026. The filing confirms the record date for CVR eligibility and describes the $30 million milestone payment contingent on FDA Priority Review Voucher issuance for briquilimab by December 31, 2028. While technically an \"Other Events\" item, the substance is a material acquisition completion with contingent consideration terms, making this a follow-up disclosure to the M\u0026A activity previously reported on the Prior Form 8-K filed July 16, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:30:55.845744+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22872,"accession_number":"0001213900-26-083563","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 8.01 disclosure concerns the contingent value rights (CVRs) structure established in connection with Jasper Therapeutics' acquisition of Kira Pharmaceuticals, which closed on July 16, 2026. The filing confirms the record date for CVR eligibility and describes the $30 million milestone payment contingent on FDA Priority Review Voucher issuance for briquilimab by December 31, 2028. While technically an \"Other Events\" item, the substance is a material acquisition completion with contingent consideration terms, making this a follow-up disclosure to the M\u0026A activity previously reported on the Prior Form 8-K filed July 16, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:30:55.845744+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-07-31"}]}